Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (4251)	7/12/1998 1:53:00 PM
From: Anthony Wong	Respond to of 9523

More Viagra clones (this one is from Egypt): Top Stories From Major Egyptian Morning Newspapers, July 12 Bloomberg News July 12, 1998, 2:08 a.m. PT Cairo, July 12 (Bloomberg) -- The following are summaries of the top stories that appeared in Egyptian papers. Misr Co. for Pharmaceuticals, a state-owned drugs company, will develop a Viagra-type medicine to be called Afroyagra that it plans to export to African, Arab and ''friendly'' countries that have approved Viagra, company chairman Moustafa Ibrahim said. He said the drug will also be sold in Egypt if the Ministry of Health approves Viagra. Egypt is yet to give permission for the sale of Viagra, the anti-impotency drug developed by Pzifer Inc. of the U.S., and has stepped up punishments for pharmacists caught selling unregistered drugs, largely to combat illegal sales of Viagra. (El Ahram) --Ben Faulks in Cairo (202) 354 2284/594 1802 through the London

To: Anthony Wong who wrote (4251)	7/12/1998 2:10:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

LA Times - Viagra Goes Political Government demands to insurers and HMOs might backfire Saturday, July 11, 1998 Last week, political leaders in both Sacramento and Washington pushed back against insurers that opted not to cover the new anti-impotence drug Viagra. The Clinton administration told state officials they must include Viagra in their Medicaid programs, and California legislators threatened legal reprisals against private insurers and HMOs that failed to cover the drug, which costs $8 to $10 per pill. "I think it's hypocritical and inhumane for any insurance company not to recognize the need [for such a treatment]," said state Sen. Diane E. Watson (D-Los Angeles). The intensity of the legislators' attack was not surprising, for political leaders in both parties made health care reform their banner issue for the November elections and, despite its dangers for some men with heart disease, Viagra was the big medical good-news story of the moment. The political heat has not generated much light, though, because legislators are studiously avoiding the underlying problem of the Viagra controversy: a lack of consensus among health care consumers and providers over which treatments should be covered because they are "medically necessary" and which ones are merely "lifestyle enhancing." In an ideal world, insurers would be able to offer all treatments. But in the real world, in which promising and pricey new drugs arrive on the market almost daily, insurers ration care to keep costs under control. By imposing particular coverage mandates, political leaders only make the problem worse, either leading insurers to drop some kinds of coverage or motivating them to opt out of a given health care market altogether. Over the last year, nearly a dozen major managed care providers, citing economic losses and cutbacks in government payments, stopped providing health care to low-income Medicaid recipients. The Clinton administration's demand that Medicaid cover Viagra is likely to lead many more insurers to opt out of the program. The National Governors Assn. argues that the mandate would impose an undue burden on the cash-strapped Medicaid program by necessitating $100 million a year more in federal and state co-payments. Federal officials are also being troublingly inconsistent, requiring states to funnel scarce resources into Viagra at the same time that they are allowing cutbacks on basic Medicaid services for people with severe disabilities. California legislators have threatened to prosecute insurers who don't cover Viagra under the state's Knox-Keene Act, which holds that "medical decisions must be independent of fiscal and administrative concerns." But soaring medical costs have given insurers no choice but to act to reduce costs. While it may be premature to revise the Knox-Keene Act, it's clearly time for state officials to encourage broad debate about which drugs--for impotence, for infertility, for mood alteration, for birth control and so on--are medically necessary. Medical necessity should not be determined by insurers alone, for the concept is more subjective than scientific, and the process of defining it should be open to public scrutiny. But before imposing sweeping coverage mandates, legislators should involve both insurers and the public in a thoughtful discussion of how the health providers can best use their limited resources to offer the broadest range of basic, medically necessary care. latimes.com:80/CNS_DAYS/980711/t000063695.html